Processing

Please wait...

Settings

Settings

1. WO2020001351 - EGFR INHIBITOR, METHOD FOR PREPARING THE SAME, AND USES THEREOF

Publication Number WO/2020/001351
Publication Date 02.01.2020
International Application No. PCT/CN2019/091972
International Filing Date 20.06.2019
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
02
specific for leukemia
C07D 401/14 (2006.01)
C07D 401/12 (2006.01)
A61K 31/506 (2006.01)
A61P 35/00 (2006.01)
A61P 35/02 (2006.01)
CPC
A61K 31/506
A61P 35/00
A61P 35/02
C07D 401/12
C07D 401/14
Applicants
  • 江苏威凯尔医药科技有限公司 JIANGSU VCARE PHARMATECH CO., LTD. [CN/CN]; 中国江苏省南京市 浦口经济技术开发区万寿路15号J2栋 Building J2, No. 15 Wanshou Road, Pukou Hi-Tech Industrial Development Zone Nanjing, Jiangsu 211800, CN
Inventors
  • 龚彦春 GONG, Yanchun; CN
  • 孟磊 MENG, Lei; CN
  • 郭其润 GUO, Qirun; CN
  • 刘永强 LIU, Yongqiang; CN
Agents
  • 江苏圣典律师事务所 JIANGSU SUNDY LAW FIRM; 中国江苏省南京 建邺区奥体大街68号新城科技园4A座6-7层胡建华 Hu Jianhua 6th Floor, Xincheng Science And Technology Park 4A Olympic Street 68# Nanjing, Jiangsu 210017, CN
Priority Data
201810704813.727.06.2018CN
201910519558.317.06.2019CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) EGFR INHIBITOR, METHOD FOR PREPARING THE SAME, AND USES THEREOF
(FR) INHIBITEUR R-EGF, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
(ZH) EGFR抑制剂及其制备和应用
Abstract
(EN)
Provided are a 2-aminopyrimidine derivative having a structure shown in a formula (I), a pharmaceutical composition containing the compound of formula (I), and the uses thereof for preparing an epidermal growth factor receptor (EGFR) kinase for preventing or treating diseases related thereto, especially uses for preventing or treating cancers related to the EGFR.
(FR)
Font l'objet de la présente invention un dérivé de 2-aminopyrimidine ayant une structure de formule (I), une composition pharmaceutique contenant ledit composé de formule (I) et ses utilisations pour la préparation d'un récepteur de facteur de croissance épidermique (R-EGF) de kinase pour la prévention ou le traitement de maladies y relatives, notamment les utilisations pour la prévention ou le traitement de cancers en rapport avec le R-EGF.
(ZH)
提供具有式(I)结构的2-氨基嘧啶衍生物、含有式(I)化合物的药物组合物及所述化合物在制备预防或治疗表皮生长因子受体(EGFR)激酶相关疾病的用途,特别是用于预防或治疗与表皮生长因子受体激酶相关的癌症的用途。
Latest bibliographic data on file with the International Bureau